Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) Cash & Equivalents (2016 - 2025)

Cellectis has reported Cash & Equivalents over the past 12 years, most recently at $61.5 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $61.5 million for Q4 2025, down 57.07% from a year ago — trailing twelve months through Dec 2025 was $61.5 million (down 57.07% YoY), and the annual figure for FY2025 was $61.5 million, down 57.07%.
  • Cash & Equivalents for Q4 2025 was $61.5 million at Cellectis, down from $143.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CLLS hit a ceiling of $185.6 million in Q4 2021 and a floor of $61.5 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $136.7 million (2023), compared with a mean of $124.1 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 46.66% in 2023 and later plummeted 57.07% in 2025.
  • Cellectis' Cash & Equivalents stood at $185.6 million in 2021, then crashed by 49.79% to $93.2 million in 2022, then skyrocketed by 46.66% to $136.7 million in 2023, then increased by 4.79% to $143.3 million in 2024, then plummeted by 57.07% to $61.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $61.5 million (Q4 2025), $143.3 million (Q4 2024), and $136.7 million (Q4 2023) per Business Quant data.